Compare Quest Diagnostics Inc (DGX) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Ulta Beauty Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Ulta Beauty Inc trades at $531.85 (market cap $23.27B). The key difference: Quest Diagnostics Inc and Ulta Beauty Inc are close in size by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| DGX | ULTA | |
|---|---|---|
Market Cap | $26.21B | $23.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $706.82 |
52-Week Low | $173.49 | $450.75 |
Enterprise Value | $31.97B | $25.35B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
ULTA stock trades at $532.14, down 3.01% today, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of $7.74, beating expectations, and maintains strong profitability with a 39.33% gross margin and 47.45% ROE. Recent news highlights Ulta's omnichannel growth strategy and the end of its Target partnership, viewed as a potential revenue opportunity by analysts.
Outlook is positive with a consensus price target of $618.29, representing 16% upside, supported by 56.53% analyst buy ratings. Risks include margin compression, with net income margin projected to drop to 9.35% in 2026, and volatile cash flows, as net cash flow turned negative in 2025. Investors should weigh strong fundamentals against competitive and execution risks in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
